Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — XOMA — Investor Presentation (September 2016)
21 slides from Xoma Royalty's investor presentation, September 2016
Slide 1: Corporate Presentation
Corporate Presentation September 2016
Slide 2: Forward-looking Statements
Forward-looking Statements Certain statements contained herein including, but not limited to, expected licensing transactions, statements related to anticipated timing of initiation and completion of clinical trials, anticipated size of clinical trials, therapeutic and market potential of XOMA’s pro
Slide 3: Investment Thesis – Driving Development in Endocrine Therapeutics
Investment Thesis – Driving Development in Endocrine Therapeutics Focus on advancing endocrine clinical portfolio • XOMA 358: Phase 2 proof-of-concept (POC) studies ongoing • XOMA 129: Confirm lead and initiate IND-enabling studies • XOMA 213: Phase 2 POC study ongoing Expand endocrine rare disease
Slide 4: XOMA’s Endocrinology Advantage
XOMA’s Endocrinology Advantage XOMA antibody discovery capabilities provide unique advantages • Allosteric modulation provides opportunity to enhance or attenuate activity without complete blockade • Successful interrogation of GPCR (G-protein- coupled receptors) targets 5 assets with multiple poten
Slide 5: XOMA’s Endocrine Portfolio
XOMA’s Endocrine Portfolio COMPOUND TARGET / POTENTIAL INDICATIONS CURRENT STAGE XOMA 358 Long-acting down-regulator of the Two Phase 2 studies ongoing [XMetD] Insulin Receptor - hypoglycemia XOMA 129 Short-acting down-regulator of the Lead identified; preclinical testing [XMetD Fabs] Insulin Recept
Slide 6: Both XOMA 358 and XOMA 129 Address Significant Needs in Hypoglycemia
Both XOMA 358 and XOMA 129 Address Significant Needs in Hypoglycemia XOMA 358 intended to prevent hypoglycemia (prophylactic), while XOMA 129 intended for treatment of hypoglycemia (acute) Increased cognitive defects in children with hypoglycemia and impacts brain development • Congenital hyperi
Slide 7: Hypoglycemia and Cardiovascular Impact
Hypoglycemia and Cardiovascular Impact Hypoglycemia implicated with excess mortality1 • Causes temporary but marked increase in stress hormones, which increase heart workload1 • Greatest risk of death and cardiac events tied to patients with lowest and highest HbA1c scores (U shaped curve)2 • Report
Slide 8: XOMA 358: Phase 2 Lead Indications
XOMA 358: Phase 2 Lead Indications Congenital Hyperinsulinism (CHI) • Chronic condition due to unregulated secretion of insulin leading to severe episodic hypoglycemia (low blood sugar) – Most common cause of hyperinsulinemic hypoglycemia in neonatal, infant and childhood periods1 • Current therapie
Slide 9: XOMA 358: CHI Disease Burden in Neonatal / Pediatric Population
XOMA 358: CHI Disease Burden in Neonatal / Pediatric Population Disease Burden Economic EconomicBurden Burden CHI places a major emotional burden on Medical Treatment: $150,000 / year patients’ families Cost of Nursing Care: $200,000 / year Parents in constant fear of hypoglycemic In event
Slide 10: XOMA 358: Phase 2 Lead Indications and Plans
XOMA 358: Phase 2 Lead Indications and Plans Post-bariatric Surgery Hyperinsulinism (PBS) • Some patients develop recurrent hypoglycemia following post-bariatric surgery − Can occur without provocation, but often after meals • Onset observed up to 3 yr post-surgery, especially after the most common
Slide 11: XOMA 358: Down-regulates Insulin Receptor
XOMA 358: Down-regulates Insulin Receptor First-in-class, fully human, monoclonal antibody • Binds to insulin receptor (INSR) and reduces glucose response • Effects can be reversed with the addition of insulin Positive Phase 1 data presented at ENDO 2015 • Post-meal glucose was higher and insulin si
Slide 12: XOMA 358: Phase 2 Study in CHI
XOMA 358: Phase 2 Study in CHI Study initiated at Children's Hospital of Philadelphia (CHOP) and at Great Ormond Street Hospital in London (GOSH) • Baseline & treatment portions occur over 3 weeks at Clinical Research Units Study expected to include 6-12 CHI patients in 2 cohorts • Patients act as t
Slide 13: XOMA 358: Phase 2 Study in PBS
XOMA 358: Phase 2 Study in PBS PBS patients experiencing symptomatic episodes of hypoglycemia Study design similar to the CHI study Several prestigious U.S. centers Patients act as their own control and treated in 2 cohorts • Enroll up to 20 patients • Hypoglycemia documented at baseline − Can be un
Slide 14: XOMA 358: CHI and PBS Trial Designs
XOMA 358: CHI and PBS Trial Designs Baseline Treatment Out-Patient Follow-up CHI: Check-in Day Day Day Day Day Day Day Day Day Day Day Day Day Day Day Day Day Day Day Day Day Day -5 -4 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 11 12 15 22 29 43 105 Required confinement at Subject may go home research facility o
Slide 15: XOMA 129: Potential Fast-Acting Treatment for Acute Severe Hypoglycemia
XOMA 129: Potential Fast-Acting Treatment for Acute Severe Hypoglycemia Highly potent XMetD Fab fragment which down regulates the INSR • Offers potential for rapid onset, improved efficacy, and tailored duration of therapy • Treatment for acute severe hypoglycemia – Severe hypoglycemia is life-threa
Slide 16: XOMA 213 for Prolactinoma: MOA Study Underway
XOMA 213 for Prolactinoma: MOA Study Underway Fully human, monoclonal antibody against the prolactin receptor • Open IND transferred to XOMA from Novartis • Significant number of patients treated for potential oncology indications for up to 48 weeks at doses up to 20x higher than predicted clinical
Slide 17: XOMA’s Endocrine Pipeline
XOMA’s Endocrine Pipeline Pre- Compound Indication Phase 1 Phase 2 Phase 3 clinical XOMA 358 CHI & PBS (INSR) XOMA 129 Short acting reversal of insulin (INSR) XOMA 213 Various hyperprolactinemias (Prolactin receptor) Hyperparathyroidism, Malignancy- Anti-PTH1R induced hypercalcemia Anti-ACTH Cushing
Slide 18: Financial Highlights
Financial Highlights $33.9M cash at June 30, 2016 Cash runway through at least first quarter of 2017 ~ 121M shares outstanding at June 30, 2016 Significant partnerships advancing non-endocrine assets 18
Slide 19: Value Created Through Partnerships
Value Created Through Partnerships Novartis anti-CD40 Antibody (CFZ533) Program • Five ongoing clinical studies • Milestones received; tiered high-single to lower mid-teen digit royalties Novartis TGFβ Antibody Program – October 2015 • $480M potential milestones; tiered mid-single to low-double digi
Slide 20: Investment Thesis – Driving Development in Endocrine Therapeutics
Investment Thesis – Driving Development in Endocrine Therapeutics XOMA 358 XOMA 129 EXPAND NON-CORE XOMA 213 (XMetD) (XMetD Fab) ENDOCRINE ASSETS Enroll patients in Conduct Enroll patients in Rare disease Partner non- Phase 2 POC pre-clinical Phase 2 MOA portfolio with core assets for studies in CHI
Slide 21: Slide 21